LC
IGMS

Lindbrook Capital’s IGM Biosciences IGMS Stock Holding History

Lindbrook Capital’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-194
Closed -$1.19K – 2860
2024
Q4 		$1.19K Buy
194
+9
+5% +$107 ﹤0.01% 2447
2024
Q3 		$3.06K Buy
+185
New +$2.03K ﹤0.01% 2210
2023
Q4 		– Sell
-150
Closed -$1.25K – 2749
2023
Q3 		$1.25K Buy
+150
New +$1.27K ﹤0.01% 2283
2023
Q2 		– Sell
-656
Closed -$9.01K – 2792
2023
Q1 		$9.01K Sell
656
-34
-5% -$703 ﹤0.01% 1511
2022
Q4 		$11.7K Sell
690
-70
-9% -$1.4K ﹤0.01% 1358
2022
Q3 		$17K Sell
760
-397
-34% -$8.02K ﹤0.01% 1066
2022
Q2 		$21K Buy
1,157
+612
+112% +$10.9K ﹤0.01% 947
2022
Q1 		$15K Buy
+545
New +$10.1K ﹤0.01% 1126

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Lindbrook Capital's IGMS Position: Q1 2025 in Review

Lindbrook Capital sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 194 shares — an estimated $1.19K sold.

Lindbrook Capital first reported a position in IGMS in Q1 2022 and held it in 8 quarters. The position peaked at $21K in Q2 2022. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • Lindbrook Capital reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 194 IGM Biosciences shares in Q1 2025, an estimated $1.19K.
  • Lindbrook Capital first reported a position in IGM Biosciences in Q1 2022 and held it in 8 quarters.
  • Lindbrook Capital's IGM Biosciences position peaked at $21K in Q2 2022.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.